$7.09
0.00% day before yesterday
NYSE, Dec 24, 09:40 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$7.09
+0.03 0.42% 1M
-2.86 28.74% 6M
-7.83 52.48% YTD
-7.64 51.87% 1Y
-20.84 74.62% 3Y
-26.16 78.68% 5Y
-26.16 78.68% 10Y
-26.16 78.68% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.00 0.00%

New AI Insights on Organon & Co. Insights AI Insights on Organon & Co.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$10.0b
Net debt
$8.2b
Cash
$672.0m
Shares outstanding
260.0m
Valuation (TTM | estimate)
P/E
3.7 | 1.9
P/S
0.3 | 0.3
EV/Sales
1.6 | 1.6
EV/FCF
17.7
P/B
2.0
Dividends
DPS
$0.34
Yield 1Y | 5Y
4.8% | 3.9%
Growth 1Y | 5Y
-69.6% | -
Payout 1Y | 3Y
33.6% | 30.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$6.3b | $6.3b
EBITDA
$1.7b | $2.0b
EBIT
$1.4b | $1.7b
Net Income
$501.0m | $991.3m
Free Cash Flow
$566.0m
Growth (TTM | estimate)
Revenue
-1.7% | -1.6%
EBITDA
-2.9% | 12.9%
EBIT
-8.9% | 17.7%
Net Income
-61.5% | 14.7%
Free Cash Flow
-12.4%
Margin (TTM | estimate)
Gross
55.0%
EBITDA
27.0% | 31.2%
EBIT
21.5%
Net
8.0% | 15.7%
Free Cash Flow
9.0%
Financial Health
Equity Ratio
3.6%
Return on Equity
183.1%
ROCE
12.5%
ROIC
8.3%
Debt/Equity
9.7
More
EPS
$1.9
FCF per Share
$2.2
Short interest
8.3%
Employees
10k
Rev per Employee
$640.0k
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

1x Buy
7%
6x Hold
40%
8x Sell
53%

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

Buy
7%
Hold
40%
Sell
53%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
6,301 6,301
2% 2%
100%
- Direct Costs 2,833 2,833
6% 6%
45%
3,468 3,468
7% 7%
55%
- Selling and Administrative Expenses 1,758 1,758
0% 0%
28%
- Research and Development Expense 405 405
14% 14%
6%
1,699 1,699
3% 3%
27%
- Depreciation and Amortization 342 342
32% 32%
5%
EBIT (Operating Income) EBIT 1,357 1,357
9% 9%
22%
Net Profit 501 501
61% 61%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
Seeking Alpha
22 days ago
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral
Business Wire
about one month ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
Neutral
Business Wire
about one month ago
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today